130 related articles for article (PubMed ID: 15813921)
1. Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma.
Gockel HR; Heidemann J; Lugering A; Mesters RM; Parwaresch R; Domschke W; Lugering N
Eur J Haematol; 2005 May; 74(5):445-7. PubMed ID: 15813921
[TBL] [Abstract][Full Text] [Related]
2. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
3. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L
Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308
[TBL] [Abstract][Full Text] [Related]
5. [Primary non-Hodgkin lymphoma of the liver: case report and review of the literature].
Nasr Ben Ammar C; Chaari N; Kochbati L; Besbes M; Maalej M
Cancer Radiother; 2006 Dec; 10(8):595-601. PubMed ID: 17137818
[TBL] [Abstract][Full Text] [Related]
6. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
[TBL] [Abstract][Full Text] [Related]
8. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
9. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.
Koh LP; Lim LC; Thng CH
Med Oncol; 2000 Aug; 17(3):225-8. PubMed ID: 10962535
[TBL] [Abstract][Full Text] [Related]
10. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.
Chu PG; Chen YY; Molina A; Arber DA; Weiss LM
Leuk Lymphoma; 2002 Dec; 43(12):2335-41. PubMed ID: 12613521
[TBL] [Abstract][Full Text] [Related]
11. Dramatical improvement of chemoresistant bone lymphoma with rituximab.
Achemlal L; Mikdame M; Nouijai A; Bezza A; El Maghraoui A
Clin Rheumatol; 2006 May; 25(3):394-5. PubMed ID: 16247586
[TBL] [Abstract][Full Text] [Related]
12. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia.
Fabbri A; Gozzetti A; Lazzi S; Lenoci M; D'Amuri A; Leoncini L; Lauria F
Clin Lymphoma Myeloma; 2006 May; 6(6):496-9. PubMed ID: 16796783
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
[No Abstract] [Full Text] [Related]
15. [A case of MALT lymphoma of the liver treated by RFA and Rituximab].
Hamada M; Tanaka Y; Kobayashi Y; Takeshita E; Joko K
Nihon Shokakibyo Gakkai Zasshi; 2006 Jun; 103(6):655-60. PubMed ID: 16800289
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
[TBL] [Abstract][Full Text] [Related]
17. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
[TBL] [Abstract][Full Text] [Related]
19. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
20. Bronchial infiltration with diffuse large B-cell lymphoma.
Hara S; Yokote T; Oka S; Akioka T; Kobayashi K; Tsuji M; Hanafusa T
Leuk Res; 2006 Oct; 30(10):1319-22. PubMed ID: 16533528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
